Atlas Trials

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Clinical trial NCT05627557 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05627557
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Childhood Idiopathic Nephrotic Syndrome
Start date
2023-03-29
Primary completion
2025-09-04
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.